ImmunityBio (IBRX) Current Leases (2016 - 2026)
ImmunityBio (IBRX) posted quarterly Current Leases of $7.6 million for Q1 2026, up 2.23% year-over-year from $7.5 million in Q1 2025, and up 1.21% quarter-over-quarter from $7.5 million in Q4 2025.
ImmunityBio (IBRX) Current Leases (2016 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Current Leases for 11 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 2.23% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (up 2.23% YoY), while the FY2025 annual figure was $7.5 million, up 0.92% from the prior year.
- Current Leases advanced to $7.6 million in Q1 2026 per IBRX's latest filing, from $7.5 million in the prior quarter.
- Across five years, Current Leases topped out at $7.6 million in Q1 2026 and bottomed at $1.4 million in Q3 2022.
- Historically, Current Leases has averaged $5.4 million across 5 years, with a median of $6.1 million in 2024.
- Annual changes were most pronounced in 2022 — Current Leases sank 55.57% — and 2023, when it soared 326.21%.
- ImmunityBio's Current Leases stood at $2.6 million in 2022, then surged by 97.89% to $5.2 million in 2023, then jumped by 42.37% to $7.5 million in 2024, then climbed by 0.92% to $7.5 million in 2025, then gained by 1.21% to $7.6 million in 2026.
- Business Quant data shows IBRX's Current Leases at $7.6 million in Q1 2026, $7.5 million in Q4 2025, and $7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 7.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.51 Mn |
| Mar 31, 2026 | 7.63 Mn |
| Dec 31, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.32 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Mar 31, 2025 | 7.46 Mn |
| Dec 31, 2024 | 7.47 Mn |
| Sep 30, 2024 | 7.03 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Mar 31, 2024 | 6.08 Mn |
| Dec 31, 2023 | 5.24 Mn |
| Sep 30, 2023 | 4.36 Mn |
| Jun 30, 2023 | 5.98 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Dec 31, 2022 | 2.65 Mn |
| Sep 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 3.51 Mn |
| Dec 31, 2021 | 3.01 Mn |
| Sep 30, 2021 | 3.07 Mn |